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Available online 12 January 2016Background: The physical health of people with schizophrenia is poor, and associated with increased morbidity
and mortality. Unhealthy lifestyles and side-effects of antipsychotic medication contribute to cardiometabolic
dysfunction. Yet it is unclear when this unhealthy proﬁle starts. We aimed to see if people at ultra-high risk for
psychosis (UHR) have increased rates of cardiometabolic risk factors.
Method: An electronic search of MEDLINE, PsycINFO, Embase and the Cochrane Central Register of Controlled
Trials was conducted on 1st May 2015 using terms associated with the ultra-high risk state and health. Eligible
studies were peer-reviewed English language research articles with populations that met at-risk diagnostic
criteria and reported cardiometabolic risk factors. A meta-analysis was conducted on smoking data, the
cardiometabolic risk factor that yielded the most studies.
Results: Forty-seven eligible studieswere identiﬁed. UHR samples had low levels of physical activity, and high rates
of smoking and alcohol abuse compared with controls. No differences were found for bodymass index. An overall
pooled rate of smoking for UHR participantswas 33% (95% CI=0.24–0.42) and signiﬁcantlymore UHR individuals
smoked compared with controls with a pooled odds ratio of 2.3 (P b 0.05; 95% CI =−1.48–3.48).
Conclusions: UHR samples display cardiometabolic risk factors which are largely modiﬁable. The UHR phase is an
important opportunity for early intervention services to improve physical health.
The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Smoking1. Introduction
The physical health of people with schizophrenia is poor. They are at
2.5 times the risk of premature mortality and their life expectancy is 10
to 30 years lower than the general population (De Hert et al., 2011a;
Saha et al., 2007; Wahlbeck et al., 2011). Despite advances in health
care and pharmaceutical developments, the life expectancy gap
continues to widen (Saha et al., 2007). A leading cause of premature
mortality is cardiovascular disease, arising from increased rates of car-
diometabolic risk factors such as obesity, hypertension, hyperglycaemia,
and dyslipidaemia (Hennekens et al., 2005;Mitchell et al., 2013), aswell
as high rates of smoking (Control and Prevention, 2013; Krishnadas
et al., 2012; McCreadie, 2003) and alcohol consumption (Addy et al.,
2012; Drake and Mueser, 2002), poor diet (McCreadie, 2003) and low
levels of physical activity (Daumit et al., 2005; Vancampfort et al., 2011).
The cause or causes of this poor cardiometabolic health is unclear.
There is evidence of hyperglycaemia, dyslipidaemia and weight gain
during the ﬁrst episode of psychosis, within the ﬁrst few weeks afterr and Mental Health, University
ord Road, Manchester M13 9PL,
.ac.uk (R. Carney).
. This is an open access article underinitiating antipsychotic treatment (Correll et al., 2014; De Hert et al.,
2006; Foley and Morley, 2011). Metabolic abnormalities increase con-
siderably with illness duration (De Hert et al., 2006, 2011b). There is
also evidence that antipsychotic-naïve individuals with non-affective
psychosis have abnormal glucose tolerance (Fernandez-Egea et al.,
2009), as do ﬁrst-degree relatives of people with schizophrenia
(Baptista et al., 2011; Spelman et al., 2007). This has led to the sugges-
tion that cardiometabolic risk factorsmay be inherent to illness progres-
sion, and enhanced by antipsychotic medication (De Hert et al., 2006).
Determining whether these factors are present before the onset of dis-
order and antipsychotic prescription could inform this debate.
One way this issue can be studied further is to consider the physical
health of people prior to psychosis onset. The ultra-high risk (UHR)
state (also known as the clinical high-risk (CHR) and at-risk mental
state (ARMS) (Fusar-Poli et al., 2013)) allows the identiﬁcation of peo-
ple in the putative prodrome for psychosis (Miller et al., 2002; Yung
et al., 1996). In order to meet UHR status an individual must exhibit
one or a combination of the following characteristics: presence of atten-
uated psychotic symptoms, brief limited intermittent psychotic symp-
toms which spontaneously resolve or genetic-risk combined with
recent decline in functioning (Yung et al., 2004). Approximately 30%
of UHR individuals transition to full-threshold psychotic disorders with-
in three years, and a large proportion of these individuals will developthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cations for early intervention and allow us to examine the physical and
psychological health of young people prior to onset of psychotic
disorder.
We aimed to systematically review the literature to examine:
(1) The prevalence of cardiometabolic risk factors in UHR populations;
(2)Whether these cardiometabolic risk factors are related to psycholog-
ical variables.2. Method
This review was conducted according to PRISMA guidelines for
reporting systematic reviews (Moher et al., 2009).2.1. Eligibility criteria
Eligible studies were original research articles published in peer-
reviewed journals, with populations meeting diagnostic criteria for ‘at-
risk’, ‘ultra-high risk’ or ‘clinical-high risk’ (or similarly deﬁned) of psy-
chosis, based on a clinically validated instrument (Daneault and Stip,
2013). Studies reporting on either clinical or behavioural cardiometa-
bolic risk factors within this population were included. Clinical assess-
ments included body mass index (BMI), weight, blood pressure (BP),
blood glucose and lipid levels. Behavioural cardiometabolic risk factors
included tobacco and alcohol use, physical activity, ﬁtness levels, and
diet. Retrospective, cross-sectional and longitudinal studies were eligi-
ble. Intervention studies were included when relevant baseline mea-
sures were reported.
Studies including only subjects at genetic-risk, not meeting formal
diagnostic criteria for being at-risk of psychosis were excluded, as
were case studies, reviews and non-English language articles. When
study samples overlapped across publications, the larger samplewas in-
cluded in the review. Studies reporting data solely relating to neuroim-
aging or neurotransmitters were excluded, as these are seen as a
biomarker or psychosis endophenotype and not necessarily a marker
of physical health.2.2. Search strategy
An electronic database searchwas conducted on 1stMay 2015 using
Ovid MEDLINE, Embase, PsycINFO and the Cochrane Central Register of
Controlled Trials (CENTRAL). The following keyword search terms were
used: ‘clinical high risk’ or ‘CHR’ or ‘ultra high risk’ or ‘UHR’ or ‘at risk
mental state’ or ‘ARMS’ or ‘prodrom*’ and ‘psychos*’ or ‘psychot*’ or
‘schizo*’ and ‘health*’. The broad search term ‘health*’ was used to en-
sure that the maximum number of potential studies were retrieved,
given the broad nature of the research topic. Reference lists of retrieved
papers were hand searched, and experts in the ﬁeld were contacted to
identify additional relevant publications.2.3. Study selection and data extraction
Three reviewers (R.C., J.C. and J.F.) independently screened articles
for eligibility. Disagreements were resolved through discussion. A tool
was developed to record: (1) study characteristics (author, year of pub-
lication, country of origin, study design); (2) sample demographics
(sample size, gender, mean age); (3) instrument used to assess at-risk
status; (4) cardiometabolic risk factors (measure, samplemean or prev-
alence reported); (5) psychological variables associated with cardio-
metabolic risk factors; and (6) summary of ﬁndings. Data extracted
was grouped into speciﬁc risk factors, and narrative synthesis was
conducted.2.4. Meta-analysis
We also aimed to determine the prevalence of cardiometabolic risk
factors in UHR samples, and compare this to healthy controls. Meta-
analytic methodswere applied to themost commonly reported risk fac-
tor, which was smoking. Individual study data for smoking prevalence
among UHR individuals were pooled using proportional meta-analysis
in StatsDirect 2.8 (StatsDirect, 2005). Additionally, an odds ratio meta-
analysis was used to compare the rates of smoking in UHRwith healthy
controls. The amount of variance between studies was examined using
Cochran's Q, and indexed using I2 (which estimates the extent of
variance caused by between-study heterogeneity rather than chance).
A DerSimonian and Laird (1986) random-effects model was applied
to all analyses to account for heterogeneity between studies
(DerSimonian and Laird, 1986).
3. Results
3.1. Search results
The study selection and exclusion process is summarised in Fig. 1.
Database searches retrieved 2281 unique citations after removal of du-
plicates, of which 1909 were excluded at the title-abstract stage and a
further 327 after full-paper review. Full text articles were excluded if
they did not examine cardiometabolic risk factors (n = 290), included
an ineligible population (n = 7), were review papers or case studies
(n= 23) or had an overlapping sample (n= 5). Two additional studies
were also excluded due to insufﬁcient detail being provided in the text
or by the authors, following contact for further clariﬁcation. Two addi-
tional eligible papers were identiﬁed from reference lists and contact
with researchers. Forty-seven unique citations were included
(Table 1). Studies were conducted in Europe (n = 30; 63.8%), North
America (n = 15; 31.9%), Australia (n = 1; 2.1%) and Asia (n = 1;
2.1%). Relevant data extracted from the studies can be found in Table 2.
3.2. Smoking
Seventeen studies reported smoking information (See Table 2). Pro-
portionate meta-analysis revealed that 33% (95% CI = 0.24–0.42; I2 =
82.4%; total pooled subjects n = 629) of UHR individuals were classed
as smokers (Fig. 2). Furthermore, UHR individuals were more likely to
be smokers compared with controls, with a pooled odds ratio of 2.3
(p b 0.05; 95% CI= 1.48–3.48; total pooled subjects n= 938), although
substantial heterogeneity was observed between samples (I2 = 78.8%)
(Fig. 3). Most studies found UHR smokers consumed more cigarettes
on average compared with controls (range 5–9 cigarettes per day;
median 6). However, many of the studies excluded individuals with
substance abuse (Amminger et al., 2010; Auther et al., 2012; Huber
et al., 2014; Kristensen and Cadenhead, 2007; Smieskova et al., 2012),
suggesting that the rate of smoking could have been even higher than
that reported, given the co-occurrence between smoking and other
substance use.
3.3. Alcohol use and abuse
Fourteen studies reported information about alcohol use (Table 2).
The percentage of peoplewhoused alcoholwas higher in control groups
compared with UHR groups. Current alcohol use varied, ranging from
30% to 88%. Quantity of alcohol consumed per week did not differ be-
tween UHR and controls, varying from 1 unit to 8 units (median 6
units).
Ten studies reported alcohol abuse or alcohol use disorders. Co-
morbid alcohol use disorders were high, reaching up to 38% (Dragt
et al., 2012) (Table 2). Self-reported rates of alcohol abuse ranged
from 16% (Huber et al., 2014) to 40% (Hutton et al., 2011). However,
the true prevalence may be higher, as many studies excluded subjects
Fig. 1. PRISMA ﬂow diagram.
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2010; Auther et al., 2012; Bernard et al., 2014; Huber et al., 2014;
Kristensen and Cadenhead, 2007; Smieskova et al., 2012).
3.4. Physiological measures
Few studies reported physiological measurements. BMI values
among the UHR group in ﬁve studies did not signiﬁcantly differ from
healthy controls, and fell within the normal weight range (range =
21–23; median 22); (Amminger et al., 2010; Bernard et al., 2014;
Hayes et al., 2014; Labad et al., 2015; Stojanovic et al., 2014). In onestudy, systolic blood pressure was signiﬁcantly lower in UHR subjects
than controls, but diastolic blood pressure was no different (Pruessner
et al., 2013). No studies documented blood glucose, cholesterol or
lipid levels.
3.5. Physical activity levels
Four studies reported physical activity (Deighton and Addington,
2013; Hodgekins et al., 2015; Koivukangas et al., 2010; Mittal et al.,
2013). UHR individuals had consistently lower levels of physical activity
(Deighton and Addington, 2013; Hodgekins et al., 2015; Koivukangas
Table 1
Studies included in review.
Study reference and country N (male/female) At-risk screening instrument Cardiometabolic risk factor Study design
Addington et al. (2007) Canada 739 (432/307) SIPS Alcohol use Longitudinal
Addington et al. (2012) Canada 468 (211/149) SIPS Alcohol use Longitudinal
Amminger et al. (2010) Austria 81 (27/54) PANSS BMI, smoking, alcohol use RCT
Andreou et al. (2014) Germany 58 (42/14)* SIPS Smoking Cross-sectional
Auther et al. (2012) USA 160 (96/64) SIPS Smoking, alcohol use Cross-sectional + longitudinal
Bernard et al. (2014) USA 58 (31/27) SIPS BMI, alcohol use Cross-sectional
Brewer et al. (2003) Australia 112 (63/49) SCID Smoking Cross-sectional + longitudinal
Brockhaus-Dumke et al. (2008) Germany 151 (106/45) BSABS Smoking Cross-sectional + longitudinal
De Koning et al. (2014) Netherlands 28 (20/8) CAARMS Smoking Cross-sectional
de la Fuente-Sandoval et al. (2011) Mexico 76 (52/24) SIPS Smoking Cross-sectional
Dean et al. (2015) USA 87 (47/40) SIPS BMI Cross-sectional + longitudinal
Deighton and Addington (2013) Canada 80 (39/41) SIPS Physical activity Cross-sectional
DeVylder et al. (2013) USA 89 (74/25) SIPS Alcohol use Cross-sectional + longitudinal
Dragt et al. (2012) Netherlands 245 (140/103) SIPS/BSABS-P Alcohol use Cross-sectional + longitudinal
Egerton et al. (2013) UK 46 (25/21) CAARMS Smoking, alcohol use Cross-sectional
Egerton et al. (2014)UK 131 (73/58) CAARMS Smoking, alcohol use Cross-sectional + longitudinal
Fusar-Poli et al. (2011) UK 41 (24/17) CAARMS Alcohol use Cross-sectional
Hayes et al. (2014) Germany 96 (65/31) CAARMS BMI, smoking Cross-sectional
Hodgekins et al. (2015) UK 6840 (3218/3622) CAARMS Physical activity Cross-sectional
Howes et al. (2011) UK 59 (37/22) CAARMS Smoking, alcohol use Longitudinal
Hsieh et al. (2012) China 155 (73/82) TP-DIS Smoking Cross-sectional + longitudinal
Huber et al. (2014) Switzerland 118 (81/37) BSIP Smoking, alcohol use Longitudinal
Hutton et al. (2011) UK 34 (25/9) CAARMS Alcohol use Cross-sectional
Koivukangas et al. (2010) Finland 6987 (3367/3620) PROD screen Physical activity Cross-sectional + longitudinal
Korkeila et al. (2013) Finland 245 (137/108) SIPS Weight, smoking, alcohol use Cross-sectional + longitudinal
Kristensen and Cadenhead (2007) USA 48 (26/22) SIPS Alcohol use, smoking Longitudinal
Labad et al. (2015) Spain 83 (56/27) CAARMS BMI, smoking, alcohol, diet Cross-sectional + longitudinal
Magaud et al. (2010) France 138 (92/46) CAARMS Alcohol use Cross-sectional
Marshall et al. (2012) Canada 48 (33/15) SIPS Alcohol use Longitudinal
Mittal et al. (2013) USA 56 (30/26) SIPS Physical activity Cross-sectional
Mizrahi et al. (2012) Canada 34 (21/13) SIPS Smoking Cross-sectional
Pruessner et al. (2013) Canada 42 (24/18) CAARMS Smoking, BP Cross-sectional
Pruessner et al. (2011) Canada 92 (49/43) CAARMS Smoking Cross-sectional
Quednow et al. (2008) Switzerland 113 (71/42) ERIraos Smoking Cross-sectional
Rapp et al. (2013) Switzerland 60 (39/21) BSIP Alcohol Cross-sectional
Russo et al. (2014) UK 120 (57/63) CAARMS Alcohol use Cross-sectional + longitudinal
Schultze-Lutter et al. (2009) Germany 948 (590/358) SIPS, BSABS, SPI-A Alcohol use Longitudinal
Smieskova et al. (2012) Switzerland 74 (50/24) BSIP Smoking, alcohol use Cross-sectional
Stojanovic et al. (2014)Spain 119 (72/47) CAARMS BMI, smoking, alcohol use Cross-sectional + longitudinal
Stone et al. (2012) UK 54 (27/27) CAARMS Smoking, alcohol use Cross-sectional
UK 54 (27/27) CAARMS Smoking, alcohol use Cross-sectional
Suridjan et al. (2013) Canada 37 (24/13) SIPS Smoking Cross-sectional
Svirskis et al. (2005) Finland 157 (55/102) SIPS Alcohol use Cross-sectional
van Tricht et al. (2013) Netherlands 98 (65/33) SIPS Smoking, alcohol use Cross-sectional
Welsh and Tifﬁn (2014) UK 30 (14/16) CAARMS Alcohol use Longitudinal
Wilquin and Delevoye-Turrell (2012) France 68 (29/39) CAARMS Alcohol use Cross-sectional
Ziermans et al. (2011) Netherlands 74 (40/34) SIPS Smoking Longitudinal
Zimbrón et al. (2013) UK 60 (36/24) CAARMS Alcohol use Cross-sectional
*missing data for gender for 2 participants.
Abbreviations: BMI: Body Mass Index; BPRS: Brief Psychiatric Rating Scale; BSABS: Bonn Scale for the Assessment of Basic Symptoms; BSIP: Basel Screening Instrument for Psychosis:
CAARMS: Comprehensive Assessment of At-Risk Mental States; ERIraos: Early Recognition Inventory; SCID: Structured Clinical Interview for DSM Disorders; SIPS: Structured Interview
for Prodromal Symptoms; SPI-A: Schizophrenia Proneness Instrument; PANSS: Positive and Negative Syndrome Scale; RCT: Randomised Controlled Trial; TP-DIS: Thought/Perception Di-
agnostic Interview Schedule.
293R. Carney et al. / Schizophrenia Research 170 (2016) 290–300et al., 2010; Mittal et al., 2013), and exercised at a lower intensity than
controls (Deighton and Addington, 2013; Mittal et al., 2013). Signiﬁ-
cantly more UHR individuals engaged in low intensity activity or seden-
tary behaviour compared with controls (Deighton and Addington,
2013). UHR males exercised more than females (Deighton and
Addington, 2013; Mittal et al., 2013). A birth cohort study found those
who later developed psychosis were more likely to be inactive during
adolescence than those who did not (Koivukangas et al., 2010). UHR in-
dividuals reported more barriers to exercise than controls, such as anx-
iety when exercising (‘I do not like how my body looks’), and fewer
reasons to exercise than controls (Deighton and Addington, 2013).
3.6. Physical ﬁtness
Cardiorespiratory ﬁtness was assessed using a Vo2 sub-max cycle-
ergometer test in 4803 adolescents (Koivukangas et al., 2010). Therewas no signiﬁcant difference in cardiorespiratory ﬁtness when individ-
uals were grouped according to at-risk status and amount of prodromal
symptoms in adolescence or whether they later developed psychosis
(Koivukangas et al., 2010). However, a separate UHR group reported
lower levels of perceived ﬁtness than controls (Deighton and
Addington, 2013).
3.7. Diet
One study reported dietary intake, and found UHR individuals con-
sumed signiﬁcantly more calories than controls (Labad et al., 2015).
3.8. Cardiometabolic risk factors and psychological variables
Low physical activity levels correlated with psychiatric symptoms
(Koivukangas et al., 2010), poor occupational functioning (Mittal et al.,
Table 2
Data extracted from studies.
Cross-sectional Studies
Study (Country) Measure UHR %
(n)
Healthy
control % (n)
Psychiatric
control
% (n)
Summary
Risk Factor—Tobacco Use
Amminger et al. (2010)—Austria % Smokers (current) 52% (42) - - The majority of cross-sectional analyses found
UHR individuals have higher rates of smoking
compared with healthy controls. Most studies
indicated that UHR smokers consumed on
average more cigarettes per day than controls
who smoked, but usually less than people with
psychosis.
Andreou et al. (2014)—Germany % Smokers (current) 50% (9) 32% (7) 61% SZ (11)
Auther et al. (2012)—USA % Smokers (current) 18% (19) 8% (4) -
% Smokers (lifetime) 34% (31) 8% (4) -
Brewer et al. (2003)—Australia % Smokers (current) 42% (34) 26% (8) -
Brockhaus-Dumke et al.
(2008)—Germany
% Smokers (current) 31% (6) 4% (2) 39% FEP
(18),
60% SZ (12)
De Koning et al. (2014)—Netherlands % Smokers (current) 50% (7) 29% (4) -
de la Fuente-Sandoval et al.
(2011)—Mexico
% Smokers (lifetime) 6% (1) 23% (9) 33% FEP (6)
Egerton et al. (2013)—UK % Smokers (current) 39% (10) 25% (5) -
Egerton et al. (2014)—UK % Smokers (current) 61% (46) 25% (14) -
Hayes et al. (2014)—Germany % Smokers (current) 33% (5) 49% (17) 65% SZ (30)
Hsieh et al. (2012)—China % Smokers (current) 17% (5) 9% (5) 9% FEP (3)
Kristensen and Cadenhead (2007)—USA % Smokers (current) 17% (8) - -
Mizrahi et al. (2012)—Canada % Smokers (current) 8% (1) 8% (1) 40% SZ (4)
Pruessner et al. (2011)—Canada % Smokers (current) 13% (4) 17% (5) 31% FEP
(10)
Pruessner et al. (2013)—Canada % Smokers (current) 14% (3) 14% (3) -
Stojanovic et al. (2014)—Spain % Smokers (current) 41% (7) 24% (6) 69% PD (53)
Stone et al. (2012)—UK % Smokers (lifetime) 70% (19) 26% (7) -
Ziermans et al. (2011)—Netherlands % Smokers (current) 21% (9) 0% (0) -
Auther et al. (2012)—USA Daily smokers 50% (15) 50% (2) -
Cigarettes per day 1–9 64% (11) 1–9 50% (2) -
10–20 30% (5) 10–20 50%
(2)
21–40 6% -
Egerton et al. (2014)—UK Cigarettes per day 6 2 -
Howes et al. (2011)—UK Cigarettes per day 5 3 4
Huber et al. (2014)—Switzerland Cigarettes per day 8 3 13 FEP
Korkeila et al. (2013)—Finland Cigarettes per day 8 - -
Stojanovic et al. (2014)—Spain Cigarettes per day 5 1 10 PD
Smieskova et al. (2012)—Switzerland Cigarettes per day 9 3 13 FEP
Stone et al. (2012)—UK Cigarettes per day 5 2 -
Kristensen and Cadenhead (2007)—USA Packs of cigarettes per day 0.13–1.5 - -
Risk Factor—Alcohol Use
Egerton et al. (2014)—UK % Alcohol use 76% (57) 84% (47) - The percentage of people reporting alcohol use
varied, but was usually higher in control groups
compared with UHR groups. Average units
consumed per week did not differ between UHR
and controls, with the exception of one study.
Rapp et al. (2013)—Switzerland % Alcohol use 49% (18) - 48% FEP
(11)
Russo et al. (2014)—UK % Alcohol use 30% (18) 57% (31) -
Smieskova et al. (2012)—Switzerland % Alcohol use 88% (29) 95% (19) 81% FEP
(17)
Zimbrón et al. (2013)—UK % Regular use 57% (17) - 52% (15)
Amminger et al. (2010)—Austria % Daily use 17% (14) - -
Stojanovic et al. (2014)—Spain % Daily use 0% (0) 4% (1) 17% (13)
Amminger et al. (2010)—Austria % Weekly use 26% (21) - -
Auther et al. (2012)—USA % Weekly use 17% (7) 12% (3) -
Rapp et al. (2013)—Switzerland % Weekly use 16% (6) - 4% FEP (4)
Auther et al. (2012)—USA % Lifetime use 44% (43) 44% (26) -
Magaud et al. (2010)—France % Occasional use 14% (11) - 18% HSC
(11)
Smieskova et al. (2012)—Switzerland % Moderate use 35% (6), 50%
(8)*
75% (15) 50% FEP
(10)
% Drunkenness 53% (9), 38%
(6)*
20% (4) 33% FEP (7)
DeVylder et al. (2013)—USA Days per month 3 5 -
Bernard et al. (2014)—USA Frequency of alcohol use (1–5) 2 1 -
Egerton et al. (2013)—UK Units per week 1 6 -
Egerton et al. (2014)—UK Units per week 8 8 -
Stone et al. (2012)—UK Units per week 7 8
Korkeila et al. (2013)—Finland Drinks per day 1 - -
Risk Factor—Alcohol Abuse
Hutton et al. (2011)—UK % Alcohol abuse 38% (13) - - Rates of self-reported alcohol abuse were high in
UHR samples and ranged between 21%-38%.
Co-morbid alcohol use disorders were also high
reaching 38% in some UHR samples.
Svirskis et al. (2005)—Finland % Alcohol abuse 21% (8) - -
Wilquin and Delevoye-Turrell
(2012)—France
% Alcohol abuse 27% (4) - 24% FEP (4)
Kristensen and Cadenhead (2007)—USA % Lifetime alcohol abuse 33% (8) - -
Huber et al. (2014)—Switzerland % Uncontrolled alcohol use 16% (7) 8% (2) 15% FEP (7)
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Table 2 (continued)
Cross-sectional Studies
Study (Country) Measure UHR %
(n)
Healthy
control % (n)
Psychiatric
control
% (n)
Summary
Addington et al. (2012)—Canada % SCID-IV Lifetime alcohol abuse 11% (40) 1% (1)
Dragt et al. (2012)—Netherlands % Alcohol use disorder 38% (76) - -
Marshall et al. (2012)—Canada % Alcohol use disorder 8% (4) - -
Schultze-Lutter et al. (2009)—Germany % Alcohol use disorder 4% (28) - -
Welsh and Tifﬁn (2014)—UK ICD-10 Alcohol dependence
syndrome
3% (1) - -
Risk Factor—Body Composition
Amminger et al. (2010)—Austria BMI 21 - - BMI values were all within the normal (healthy)
weight range of 19–25 and were not signiﬁcantly
different to healthy controls or people with
psychosis/schizophrenia.
Bernard et al. (2014)—USA BMI 22 24 -
Hayes et al. (2014)—Germany BMI 23 23 23 SZ
Stojanovic et al. (2014)—Spain BMI 22 22 24 PD
Korkeila et al. (2013)—Finland Average weight 68 kg - -
Risk Factor—Physical Activity
Hodgekins et al. (2015)—UK Hours of sport per week 1.7 2.0 3.2 FEP The amount of physical activity was signiﬁcantly
lower in the UHR group compared with healthy
controls. UHR individuals reported signiﬁcantly
more barriers and fewer reasons to exercise
compared with controls.
Mittal et al. (2013)—USA Minutes of weekly activity 364 458 -
Deighton and Addington
(2013)—Canada
Duration (1–4) 2.5 2.9 -
Frequency (1–4) 2.4 2.8 -
Intensity (1–4) 3.0 3.4 -
Amount of barriers to exercise 445 332 -
Amount of reasons to exercise 283 384 -
Longitudinal studies
Study (country) Measure UHR-P UHR-NP HC Time-point
assessed
Summary
Risk Factor—Smoking
Brewer et al. (2003)—Australia % Smokers 41% (9) 42% (25) 26% (8) Baseline Most studies found UHR-P had lower rates of
smoking at baseline compared with UHR-NP.
However, those who did transition generally
smoked more per day or had higher lifetime
rates than controls, and non-transition subjects.
Brockhaus-Dumke et al.
(2008)—Germany
% Smokers 29% (6) 33% (6) 4% (2) Baseline
Ziermans et al. (2011)—Netherlands % Smokers 17% (1) 22% (8) 0% (0) Baseline
17% (1) 33% (12) 3% (1) Follow-up (2 year)
Howes et al. (2011)—UK Cigarettes per day 5 5 3 Baseline
Labad et al. (2015)—Spain Cigarettes per day 7 4 2 Baseline
Brewer et al. (2003)—Australia Lifetime quantity
(cigarettes per
day × years of use)
94 87 43 Baseline
Risk Factor—Alcohol Use
Howes et al. (2011)—UK Units per week 7 5 10 Baseline UHR-P consumed more units per week on
average than UHR-NP.Labad et al. (2015)—Spain Units per day 0 0 0 Baseline
Risk Factor—Body Composition
Labad et al. (2015)—Spain BMI 21 22 22 Baseline BMI did not differ at baseline according to later
transition.
Risk Factor—Physical Activity
Koivukangas et al. (2010)—Finland % Inactive 40% (13) - 20%
(1410)
Baseline 40% of a birth cohort who went on to experience
psychosis were inactive at adolescence,
compared with 20% who did not experience
psychosis.
Risk Factor—Physical Fitness
Koivukangas et al. (2010)—Finland % Low physical
ﬁtness
46% (6) - 33%
(1569)
Baseline 46% of a birth cohort who went on to experience
psychosis had low physical ﬁtness at
adolescence, compared with 33% who did not
experience psychosis.
Risk Factor—Diet
Labad et al. (2015)—Spain Calories per day 2740
kcal
2368
kcal
1788 kcal Baseline UHR-P consumed more calories on average per
day than controls and those who did not
transition. Both groups had signiﬁcantly higher
calorie intake than controls.
Protein intake per
day
98 g 94 g 87 g Baseline
Abbreviations: BMI: Body Mass Index; FEP: First-episode psychosis; HC: Healthy control; HSC: Help-seeking control; kcal: kilocalories; PD: Psychotic disorder; SZ: Schizophrenia; UHR:
Ultra-high risk; UHR-P: Ultra-high risk who transitioned to psychosis; UHR-NP: Ultra-high risk who did not transition to psychosis.
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Individuals who transitioned to psychosis also smoked more cigarettes
on average per day (Labad et al., 2015), had higher rates of overall ciga-
rette use (Brewer et al., 2003), consumedmore alcoholic units per week(Labad et al., 2015) and had a higher daily calorie intake (Labad et al.,
2015) when assessed during the UHR phase. However, overall smoking
status was not associated with transition (Brewer et al., 2003; Ziermans
et al., 2011).
Fig. 2. Summary of Smoking Rates of UHR samples.
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This is the ﬁrst review assessing cardiometabolic risk factors and
physical health in the at-risk population. UHR individuals have high
rates of behavioural cardiometabolic risk factors with elevated rates of
smoking, physical inactivity and alcohol abuse, butwere notmore over-
weight than controls. Longitudinal studies indicate that the increased
unhealthy lifestyle factors may be associated with later transition to
psychosis. These ﬁndings are consistent with a recent meta-analysis
that found smoking may be a causative factor in the onset of psychosis
(Gurillo et al., 2015).
4.1. Why do UHR individuals have unhealthy lifestyles?
4.1.1. Smoking
UHR individuals have high levels of depression, anxiety and negative
symptoms (Fusar-Poli et al., 2014; Rietdijk et al., 2013; Yung et al.,
2004). Smokingmay reduce these symptoms through relaxation or alle-
viation of boredom (the self-medication hypothesis) (Kumari and
Postma, 2005). Additionally, nicotine consumption may help to reduce
deﬁcits in information processing, by acting on nicotinic receptors in
the temporal cortex (Bridgman et al., 2014; De Luca et al., 2004).
It could be that there is a shared proneness to developing schizo-
phrenia (or sub-threshold psychotic symptoms) and smoking. There
may be underlying neurobiological causes for this vulnerability (de
Leon and Diaz, 2005), or it may occur through social mechanisms. For
example, it is known that social deprivation increases psychosis risk
through social defeat, poverty and increased likelihood of trauma
(Allardyce et al., 2005; Cotter et al., 2015) and that socially deprived
areas have high rates of unhealthy lifestyle factors including smoking,substance abuse and physical inactivity (Barbeau et al., 2004; Hanson
and Chen, 2007; Wardle and Steptoe, 2003).
Finally, it could be that smoking increases the risk of developing
schizophrenia through inducing dopamine dysregulation in the brain
(Gurillo et al., 2015), and the UHR group represents the ﬁrst manifesta-
tion of the illness. However, further research is needed to explain the re-
lationship between smoking and schizophrenia.
4.1.2. Physical inactivity
We can speculate that increased levels of depression, anxiety and
negative symptoms in the UHR group contribute to decreased motiva-
tion to exercise and increased sedentary behaviour. UHR individuals
often report reduced vitality levels, or motivation, energy and drive
(Bechdolf et al., 2005; Grano et al., 2014; Hauser et al., 2009;
Ruhrmann et al., 2008). Additionally, as noted above, factors such as so-
cial deprivation may present a shared risk for both physical inactivity
and schizophrenia (Barbeau et al., 2004).
Exercise decreases inﬂammation and increases Brain Derived Neu-
rotrophic Factor (BDNF) (Cotman and Berchtold, 2002; Mondelli et al.,
2011; Singh and Chaudhuri, 2014). We could speculate that there is a
link between physical inactivity, increased inﬂammation and decreased
BDNF. However, it is unclear whether a reduction in physical activity
has a causative role in increasing inﬂammation or whether it is a result
of underlying neuro-inﬂammation occurring as the illness progresses.
4.1.3. Alcohol use and diet
Preliminary evidence indicates that UHR individuals may be more
likely to abuse alcohol and consume more calories than generally
healthy populations. The reported rates of alcohol abuse and misuse
were higher than that of the general public. For example, it is estimated
Fig. 3. Odds ratio of smoking status in UHR individuals and control groups.
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young people 16 to 24 years engage in hazardous drinking (McManus
et al., 2009). Therefore, althoughmany studies did not include a control
group, the rates of alcohol abuse were often higher compared with the
general population, reaching up to 38% for alcohol abuse (Hutton
et al., 2011) and alcohol abuse disorders (Dragt et al., 2012). We
can again speculate that this may be attributable to social and environ-
mental factors, since low socioeconomic status is a common risk factor
for psychosis and is also associated with substance misuse and poor
diet (Darmon and Drewnowski, 2008; Galea et al., 2004; Marcenko
et al., 2000). However, it could also be that eating a healthy diet has a
neuroprotective effect, such as the consumption of omega-3 fatty
acids and other vitamins, (McGrath et al., 2004; Peet, 2008). This arises
from recentﬁndingswhich suggest treatmentwith long-chain omega-3
fatty acids could lead to longitudinal symptomatic and functional im-
provements in UHR individuals (Amminger et al., 2010, 2015a, 2015b).
4.2. Limitations
The scope of the review was intentionally broad. Many studies of
varied content andmethodological designwere included, making direct
comparisons difﬁcult. This is also reﬂected in the high levels of between
study heterogeneity reported in themeta-analyses. This is likely to have
been driven by both clinical and methodological differences across the
studies with regards to UHR screening measures, study inclusion
criteria (such as the rates of comorbid disorders and whether those
with substance use disorders were included), recruitment settings and
methods of data collection. Quality assessments were not conducted,
as most information came from demographic assessments and not the
studies' primary outcomes. Most studies were cross-sectional and sam-
ple size was often underpowered to ﬁnd signiﬁcant differences. Control
groups varied, sometimes including help-seeking controls which made
comparisons difﬁcult.4.3. Clinical implications
High rates of cardiometabolic risk factors observed in the UHR group
are due to unhealthy lifestyle factors. These behaviours are potentially
modiﬁable. Thus, the UHR phase is an important opportunity for early
intervention to improve physical health, as UHR groupsmay be amena-
ble to lifestyle interventions, including smoking cessation programmes,
exercise promotion and healthy diet. Although a large proportion of
UHR individuals will not develop a psychotic disorder, many go on to
develop anxiety, mood and substance use disorders (Addington et al.,
2011) and many will continue to function poorly, regardless of transi-
tion or symptomatic remission (Cotter et al., 2014). Therefore, even
among so-called “false positives” (Yung et al., 1996), interventions to
improve physical health are likely to be of beneﬁt and may improve co-
morbid symptoms such as depression (Cooney et al., 2013), along with
physical health.4.4. Future research
A current gap in the literature is the prevalence and trajectory of
plasma measurements of lipid and glucose, and insulin insensitivity
in the UHR group. This is of particular interest as it would allow us
to examine the possible effects of vulnerability to psychosis on
these metabolic markers without confounding effects of antipsy-
chotic medication. Further research is also required in the UHR
group to assess cardiometabolic risk factors discussed in this review,
such as physical activity and ﬁtness, diet and physiological measure-
ments. Examination of the association between these metabolic and
other physical health variables with psychiatric symptoms and
transition to psychotic disorder is also of interest and may highlight
possible mechanisms underlying the link between unhealthy behav-
iours and psychosis onset.
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